Article Text

Download PDFPDF
Obesity, Type 2 diabetes and metformin

Statistics from

In March 2014, Archivist reported on a systematic review of the use of metformin in treating morbid obesity: the conclusion was that it was of limited value (doi: 10.1136/archdischild-2014-305957). This has now been added to by a trial from Spain (Pastor-Villaescusa B et al. Pediatrics 2017. doi:10.1542/peds.2016-4285). In a double-blind trial, 140 young people with a BMI > 95th centile, half of whom were pre-pubertal, were randomised: they received either 500 mg twice daily of metformin or placebo, for 6 months. The outcomes differed depending on pubertal status: in the pre-pubertal group, the BMI z-score was reduced by 0.2 more …

View Full Text

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.